Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/10/2023 | $160.00 → $200.00 | Buy → Hold | Jefferies |
| 7/20/2022 | $51.00 | Buy | Goldman |
| 6/10/2022 | $53.00 | Overweight | Piper Sandler |
| 3/10/2022 | $50.00 → $52.00 | Outperform | Credit Suisse |
| 3/10/2022 | $42.00 → $53.00 | Overweight | Wells Fargo |
| 3/10/2022 | $47.00 → $55.00 | Outperform | SVB Leerink |
| 2/11/2022 | $62.00 | Buy | BTIG |
| 12/13/2021 | $46.00 | Outperform | RBC Capital Mkts |
Jefferies downgraded Prometheus Biosciences from Buy to Hold and set a new price target of $200.00 from $160.00 previously
Goldman initiated coverage of Prometheus Biosciences with a rating of Buy and set a new price target of $51.00
Piper Sandler initiated coverage of Prometheus Biosciences with a rating of Overweight and set a new price target of $53.00
4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
Cellino Biotech, Inc., a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241024933617/en/Chris Gibson, Ph.D., Co-Founder & CEO, Recursion. (Photo credit: Recursion) Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven drug discovery. Dr. Gibson has led a number of key partnerships for Recursion with leading pharma and tech companies, including Roche/Genente
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn's disease and other autoimmune conditions Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. ("Prometheus") (NASDAQ:RXDX) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or traded on the Nasdaq Global Market. "The Prometheus acquisition accelerates our growing presence in immunology, augments our diverse pipeline and increases our ability to deliver patient value. This transaction is anoth
SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today reported financial results for the quarter ended March 31, 2023. Prometheus to be Acquired by Merck On April 15, 2023, Merck and Prometheus Biosciences entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion. The transaction is expected to close in the th
Cellino Biotech, Inc., a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241024933617/en/Chris Gibson, Ph.D., Co-Founder & CEO, Recursion. (Photo credit: Recursion) Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven drug discovery. Dr. Gibson has led a number of key partnerships for Recursion with leading pharma and tech companies, including Roche/Genente
- Initiated Phase 2 study of PRA023 and its companion diagnostic in Ulcerative Colitis (UC) and Phase 2a study of PRA023 and its companion diagnostic in Crohn's disease (CD) - - Phase 1a trial results of PRA023 in normal healthy volunteers expected in fourth quarter 2021 - - Strong cash position of $304 million as of June 30, 2021 - SAN DIEGO, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting first with inflammatory bo
Eleusis, a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, today announced the appointment of four highly experienced business leaders to its board of directors. The new directors' deep expertise building high-growth, high-impact life science companies complements Eleusis's world-class leadership team. The appointees include: David Socks, former CEO of Phathom Pharmaceuticals, joining as Chair of the board Robert Hershberg, M.D., Ph.D., former CBO and CSO of Celgene John Tucker, CEO of SC Pharmaceuticals Esther van den Boom, Managing Partner at van den Boom & Associates "We are delighted to welcome these four exceptional d
– ARTEMIS-UC trial met primary endpoint with 26.5% of patients on PRA023 achieving clinical remission compared to 1.5% of patients on placebo at Week 12 (p<0.0001) – – ARTEMIS-UC Cohort 1 met all ranked secondary endpoints – – APOLLO-CD trial showed 26.0% endoscopic response and 49.1% clinical remission rates (p=0.002 and p<0.001, respectively, compared to prespecified historical placebo rates) – – PRA023 demonstrated favorable safety and tolerability results across both studies with no safety signal identified – – ARTEMIS-UC Cohort 1 interim analysis suggests a trend towards increased PRA023 response in CDx+ patients over all comers – – PRA023 showed a significant impact on multiple m
Phase 1 trial achieved primary objective of safety and tolerability and demonstrated favorable outcomes on other key endpoints, including target engagement and immunogenicity Discussion of Phase 1 results and rationale around SSc-ILD as new PRA023 indication to be presented in conference call scheduled today at 8:00 AM EST SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today reported positive topline results fro
SC 13G/A - Prometheus Biosciences, Inc. (0001718852) (Subject)
SC 13G/A - Prometheus Biosciences, Inc. (0001718852) (Subject)
SC 13G/A - Prometheus Biosciences, Inc. (0001718852) (Subject)
15-12G - Prometheus Biosciences, Inc. (0001718852) (Filer)
25-NSE - Prometheus Biosciences, Inc. (0001718852) (Subject)
S-8 POS - Prometheus Biosciences, Inc. (0001718852) (Filer)
In a rare move to block a large pharma deal, the U.S. Federal Trade Commission would sue to stop Amgen Inc's (NASDAQ:AMGN) $28 billion takeover of Horizon Therapeutics PLC (NASDAQ:HZNP). Reuters reported that the FTC said Amgen could use its solid position to pressure insurance companies and pharmacy benefit managers into favorable terms for Horizon's two key products - thyroid eye disease treatment Tepezza and gout drug Krystexxa. FTC Bureau of Competition Director Holly Vedova, in the Reuters report, called the lawsuit "the FTC's first challenge to a pharmaceutical merger in recent memory." "Rampant consolidation in the pharmaceutical industry has given powerful companies a pass to exor
RBC Capital analyst Gregory Renza maintains Prometheus Biosciences (NASDAQ:RXDX) with a Sector Perform and maintains $200 price target.
Upgrades For Tabula Rasa HealthCare Inc (NASDAQ:TRHC), SVB Leerink upgraded the previous rating of Market Perform to Outperform. Tabula Rasa HealthCare earned $0.02 in the first quarter, compared to $0.68 in the year-ago quarter. The current stock performance of Tabula Rasa HealthCare shows a 52-week-high of $6.69 and a 52-week-low of $2.09. Moreover, at the end of the last trading period, the closing price was at $5.52. According to Maxim Group, the prior rating for Paltalk Inc (NASDAQ:PALT) was changed from Hold to Buy. Paltalk earned $0.08 in the first quarter, compared to $0.08 in the year-ago quarter. The current stock performance of Paltalk shows a 52-week-high of $4.60 and a 52-wee